SecBot SecBot
Biotech Drug Report Generated Nov 7, 2026

VIR-5500

VIR·Vir Biotechnology, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 1
Time to market
VIR-5500 is in Phase 1 dose expansion. Pivotal Phase 3 trials are anticipated to begin in 2027. Even with Fast Track designation, approval is likely several years away, assuming successful development.
Why 4/10
VIR-5500 has no hard dated binary catalyst (PDUFA, pivotal readout, or AdComm) within the next ~12 months. Phase 3 trials are anticipated to start in 2027, but that is a program initiation, not a binary data event. Updated Phase 1 dose expansion data may emerge but has no scheduled date. The drug is a meaningful pipeline asset for Vir but is not the company's primary near-term catalyst (the hepatitis delta ECLIPSE program has Phase 3 topline data due Q4 2026). ImpactScore of 4 reflects an early-stage drug with no imminent binary catalyst.
Actionable Insight NEUTRAL

VIR-5500 is an early-stage but promising PSMA-targeted T-cell engager with strong Phase 1 data and a deep-pocketed partner in Astellas. The next meaningful catalyst is updated Phase 1 dose expansion data, but no date has been set. For Vir Biotechnology as a whole, the more immediate binary event is the ECLIPSE 1 Phase 3 topline readout for hepatitis delta expected in Q4 2026, which is likely to drive near-term share price action more than VIR-5500 news.

Price Chart

Loading chart...

Executive Summary

VIR-5500 is an investigational PSMA-targeted, dual-masked T-cell engager being developed by Vir Biotechnology (Nasdaq: VIR) in collaboration with Astellas Pharma for metastatic prostate cancer. Phase 1 dose-escalation data showed encouraging efficacy (82% PSA50 response rate, 45% objective response rate at higher doses) with a favorable safety profile and no dose-limiting toxicities. The drug received FDA Fast Track designation in October 2026. A global collaboration with Astellas (up to $1.7 billion total value, $335 million upfront) provides financial and development support, with Phase 3 trials expected to begin in 2027. However, VIR-5500 remains early-stage with no near-term binary catalyst, and Vir's stock is more immediately driven by the company's hepatitis delta program (ECLIPSE Phase 3 data due Q4 2026).

How It Works

VIR-5500 is a bispecific T-cell engager (TCE), a type of immunotherapy that works like a bridge. One end of the drug grabs onto PSMA, a protein found on prostate cancer cells, while the other end grabs onto T-cells (immune cells). This forces the T-cells to attack the cancer. The drug uses a "dual-masked" PRO-XTEN technology that keeps it inactive until it reaches the tumor environment, where enzymes naturally found near tumors unmask it. This design aims to reduce side effects by limiting immune activation to the tumor site rather than throughout the body.

Trial Status

VIR-5500 is being studied in an open-label, non-randomized Phase 1 trial (NCT05997615) in patients with metastatic castration-resistant prostate cancer (mCRPC). Dose escalation in late-line mCRPC (58 patients as of January 2026) showed no dose-limiting toxicities and dose-dependent anti-tumor activity. At doses of 3,000+ ug/kg every three weeks, 82% of patients achieved a 50% or greater PSA decline (PSA50) and 45% had objective responses per RECIST criteria. Dose expansion began in April 2026, adding combination cohorts with enzalutamide, docetaxel, and darolutamide, and expanding into earlier-line mCRPC and metastatic hormone-sensitive prostate cancer (mHSPC).

The Two-Sided Case

▲ Bull Case5
Early Phase 1 data showed compelling efficacy: 82% PSA50 response rate and 45% objective response rate at higher doses in heavily pretreated patients who had exhausted other options, with no dose-limiting toxicities observed.
The dual-masked PRO-XTEN technology appears to mitigate the cytokine release syndrome risk that has plagued other T-cell engagers, potentially giving VIR-5500 a best-in-class safety profile.
The Astellas collaboration (up to $1.7B total, with $335M upfront/near-term) provides substantial validation, co-development funding, and a large-pharma commercialization partner with a track record in prostate cancer (Xtandi).
FDA Fast Track designation (October 2026) accelerates development and review timelines.
The drug is being studied across the prostate cancer treatment continuum (late-line mCRPC, early-line mCRPC, and mHSPC), expanding its potential market opportunity.
▼ Bear Case5
VIR-5500 is still in Phase 1 with a small sample size (58 patients in dose escalation); efficacy and safety need confirmation in larger, randomized trials.
Phase 3 trials are not expected to start until 2027, meaning no near-term binary catalyst and years until potential commercialization.
Competition in PSMA-targeted therapies is intensifying: Novartis's Pluvicto (radioligand therapy) is already approved, and other T-cell engagers (e.g., GSK's GSK5458514) are entering the clinic.
Vir Biotechnology has multiple pipeline priorities (hepatitis delta ECLIPSE Phase 3 readouts imminent), and oncology TCE programs are still early-stage, so VIR-5500 is not the company's primary near-term value driver.
The stock trades near its 52-week high ($12.21 vs $12.45 high) after a 10.8% single-day surge, suggesting positive news may already be priced in for the near term.

Upcoming Catalysts

  • Updated Phase 1 dose expansion data (no specific date announced)
  • Initiation of Phase 3 pivotal trials anticipated in 2027

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Vir Biotechnology, Inc. 8-K VIR ·Originating report

Sources · 10

Hover a chip for the title
1 investors.vir.bio2 investors.vir.bio3 newsroom.astellas.com4 fiercebiotech.com5 ascopubs.org6 urotoday.com7 investors.vir.bio8 businesswire.com9 cancernetwork.com10 biospace.com